FOCUS on Drug Failures. Yesterday Sanofi provided an update on tolebrutinib (SAR442168, a Bruton tyrosine kinase inhibitor), in primary progressive multiple sclerosis. Results from the PERSEUS phase 3 study (Clinical study identifier: NCT04458051) showed that tolebrutinib did not meet its primary endpoint in delaying time to 6-month composite confirmed disability progression in participants with primary progressive multiple sclerosis (PPMS). Based on these results Sanofi will not pursue regulatory registration for tolebrutinib in PPMS.
Focus Biomolecules can supply tolebrutinib for research applications to learn more about BTK as a drug target. For more information, contact us.
